Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

721 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study.
Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P, Conti A, Gambardella A, Burlando M, Narcisi A, Offidani A, Balestri R, Bardazzi F, Prignano F, Mugheddu C, Romanelli M, Malara G, Schinzari G, Fargnoli MC. Pellegrini C, et al. Among authors: gambardella a. Dermatol Ther (Heidelb). 2022 Nov;12(11):2613-2626. doi: 10.1007/s13555-022-00797-9. Epub 2022 Sep 28. Dermatol Ther (Heidelb). 2022. PMID: 36169883 Free PMC article.
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study.
Chiricozzi A, Gori N, Narcisi A, Balato A, Gambardella A, Ortoncelli M, Marzano AV, Balestri R, Palazzo G, Pellegrino M, Romanelli M, Tripepi G, Peris K, Costanzo A; ACCURATE Group. Chiricozzi A, et al. Among authors: gambardella a. Drugs R D. 2022 Sep;22(3):245-252. doi: 10.1007/s40268-022-00396-1. Epub 2022 Aug 3. Drugs R D. 2022. PMID: 35922713 Free PMC article.
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.
Fargnoli MC, Esposito M, Dapavo P, Parodi A, Rossi M, Tiberio R, Dastoli S, Offidani AM, Argenziano G, Gisondi P, Lo Schiavo A, Loconsole F, Pella P, Bardazzi F, Cusano F, Gattoni M, Nacca M, Cannavò SP, Pellegrini C, Costanzo A; BRILLIANT Working Group. Fargnoli MC, et al. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):693-700. doi: 10.1111/jdv.16931. Epub 2020 Oct 13. J Eur Acad Dermatol Venereol. 2021. PMID: 32916767
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
Conti A, Peccerillo F, Amerio P, Balato A, Bardazzi F, Bianchi L, Burlando M, Cannavò SP, Chiricozzi A, Dapavo P, De Simone C, Fargnoli MC, Gambardella A, Gisondi P, Malagoli P, Malara G, Mugheddu C, Offidani AM, Piaserico S, Prignano F, Stingeni L, Pellacani G. Conti A, et al. Among authors: gambardella a. Br J Dermatol. 2019 Jun;180(6):1547-1548. doi: 10.1111/bjd.17580. Epub 2019 Feb 21. Br J Dermatol. 2019. PMID: 30578668 No abstract available.
Brodalumab treatment in psoriasis patients with severe renal failure.
Ribero S, Conti V, Gambardella A, DE Rosa AB, Dapavo P, Argenziano G. Ribero S, et al. Among authors: gambardella a. Ital J Dermatol Venerol. 2021 Jun;156(3):406-408. doi: 10.23736/S2784-8671.20.06719-X. Epub 2020 Nov 23. Ital J Dermatol Venerol. 2021. PMID: 33228335 No abstract available.
Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.
De Simone C, Dapavo P, Malagoli P, Martella A, Campanati A, Campione E, Errichetti E, Franchi C, Gambardella A, Megna M, Osti F, Ribero S, Zagni G, Calzavara-Pinton P, Fabbrocini G; PAM Italian Working Group; Amoruso GF, Baglieri F, Biamonte AS, Bianchelli T, Bigi L, Bortoli J, Brunetti B, Buligan C, Cagni E, Calderoni O, Calzavara-Pinton P, Campanati A, Caputo A, Carrera CG, Carugno A, Chersi K, Cicchelli S, De Natale F, De Simone C, Dapavo P, Di Maria D, Errichetti E, Fabbrocini G, Ferrari AS, Fogli E, Forconi R, Franchi C, Galeazzi A, Gambardella A, Giovannini A, Giura MT, Iuculano M, Lazzaretti G, Leporati C, Magnanini M, Malagoli P, Marconi B, Martella A, Maruccia A, Megna M, Miglietta R, Minuti A, Mocci L, Modica S, Narcisi A, Odorici G, Osti F, Pazzaglia M, Peila R, Pertusi G, Pezza M, Pezzullo E, Puccia N, Raulo U, Ribero S, Rossi M, Rusignuolo S, Sapienza G, Savarese C, Scalisi M, Strippoli D, Stroppiana E, Tiberio R, Trischitta A, Tucci MG, Vaira F, Verrone A, Villa L, Zagni F, Zoccali A. De Simone C, et al. Among authors: gambardella a. Int J Dermatol. 2022 Dec;61(12):1543-1551. doi: 10.1111/ijd.16192. Epub 2022 May 24. Int J Dermatol. 2022. PMID: 35609147 Free PMC article.
Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, Galluccio AG, Gambardella A, Lembo S, Mozzillo R, Scotto Di Luzio G, Fabbrocini G, Balato N. Megna M, et al. Among authors: gambardella a. Expert Opin Biol Ther. 2019 Aug;19(8):855-861. doi: 10.1080/14712598.2019.1622678. Epub 2019 May 29. Expert Opin Biol Ther. 2019. PMID: 31140882
Real-life efficacy of guselkumab in patients with early psoriatic arthritis.
Pantano I, Mauro D, Romano F, Gambardella A, Valenti M, Simone D, Iacono D, Costanzo A, Argenziano G, Ciccia F. Pantano I, et al. Among authors: gambardella a. Rheumatology (Oxford). 2022 Mar 2;61(3):1217-1221. doi: 10.1093/rheumatology/keab509. Rheumatology (Oxford). 2022. PMID: 34152379
721 results